Acneiform eruptions induced by cetuximab;Éruptions acnéiformes induites par le cétuximab

Annales de Dermatologie et de Venereologie

Volumn 130, Issue 4, 2003, Pages 443-446

  Walon, L ^a   Gilbeau, C ^a   Lachapelle, J M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BISOPROLOL; CETUXIMAB; CORTICOSTEROID; CYANOCOBALAMIN; CYPROTERONE ACETATE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ESTRADIOL VALERATE; FUMARIC ACID; HALOGEN; IMMUNOSUPPRESSIVE AGENT; LEVOTHYROXINE SODIUM; LITHIUM; MINOCYCLINE; TUBERCULOSTATIC AGENT; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACNE; ADENOCARCINOMA; ADULT; AGED; ANTIGEN BINDING; ARM; ARTICLE; BACTERIUM CULTURE; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL EXAMINATION; COLORECTAL CARCINOMA; COMEDO; DRUG BINDING; DRUG ERUPTION; DRUG MECHANISM; FACE; FEMALE; FOLLICULITIS; FUNGUS CULTURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; MALE; NEUTROPHIL; PAPULE; PERIODIC ACID SCHIFF STAIN; PRURITUS; PUSTULE; THORAX; TRUNK; BIOPSY; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DIFFERENTIAL DIAGNOSIS; MIDDLE AGED; PATHOLOGY; SKIN;

ACNEIFORM ERUPTIONS; ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOPSY; COLORECTAL NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; SKIN;

EID: 0038377345     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Baselga J. The EGFR as a target for anticancer therapy, focus on cetuximab. Eur J Cancer 2001;37 (suppl4):16s-22s.
2. Pederson MW, Meltorn M, Damstrup L, Poulsen HS. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 2001;12:745-60.
3. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin Oncol 2001;19:3234-43.
4. Baselga J. New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol 2000;18 (Suppl. 21):54s-59s.
5. Seymour LK. Epidermal growth factor receptor as a target: recent developments in the search for effective new anticancer agents. Curr Drug Targets 2001;2:117-33.
6. Albanell J, Codony-Servat J, Rojo F, Del-Campo JM, Sauleda S, Anido J et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001;61:6500-10.
7. Kimyai-Asodi A, Jih MH. Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 2002;138:129-30.
8. Busamn KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144:1169-76.